2.84
3.65%
+0.10
After Hours:
2.81
-0.03
-1.06%
T2 Biosystems Inc stock is currently priced at $2.84, with a 24-hour trading volume of 137.77K.
It has seen a +3.65% increased in the last 24 hours and a -0.70% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.74 pivot point. If it approaches the $2.88 resistance level, significant changes may occur.
Previous Close:
$2.74
Open:
$2.76
24h Volume:
137.77K
Market Cap:
$24.97M
Revenue:
$7.19M
Net Income/Loss:
$-50.08M
P/E Ratio:
-0.0099
EPS:
-286.9
Net Cash Flow:
$-48.33M
1W Performance:
-4.05%
1M Performance:
-0.70%
6M Performance:
-49.38%
1Y Performance:
-91.39%
T2 Biosystems Inc Stock (TTOO) Company Profile
Name
T2 Biosystems Inc
Sector
Industry
Phone
781 761 4646
Address
101 Hartwell Avenue, Lexington
T2 Biosystems Inc Stock (TTOO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-27-21 | Downgrade | Alliance Global Partners | Buy → Neutral |
Oct-08-20 | Initiated | BTIG Research | Buy |
Nov-26-19 | Downgrade | Janney | Buy → Neutral |
Aug-01-19 | Downgrade | Alliance Global Partners | Buy → Neutral |
Jul-31-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jul-31-19 | Downgrade | Janney | Buy → Neutral |
May-16-19 | Initiated | Alliance Global Partners | Buy |
Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
Jun-01-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
May-30-18 | Reiterated | H.C. Wainwright | Buy |
May-29-18 | Reiterated | WBB Securities | Strong Buy |
Mar-29-18 | Reiterated | H.C. Wainwright | Buy |
Jan-29-18 | Initiated | Goldman | Neutral |
Oct-18-17 | Initiated | H.C. Wainwright | Buy |
Mar-15-17 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Nov-10-16 | Resumed | Leerink Partners | Mkt Perform |
Nov-02-16 | Reiterated | Cantor Fitzgerald | Buy |
Jul-20-16 | Upgrade | WBB Securities | Buy → Strong Buy |
Jun-22-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
Apr-12-16 | Reiterated | Canaccord Genuity | Buy |
Feb-17-16 | Initiated | WBB Securities | Speculative Buy |
View All
T2 Biosystems Inc Stock (TTOO) Latest News
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
GlobeNewswire Inc.
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
GlobeNewswire Inc.
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
GlobeNewswire Inc.
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
GlobeNewswire Inc.
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
GlobeNewswire Inc.
T2 Biosystems Inc Stock (TTOO) Financials Data
T2 Biosystems Inc (TTOO) Revenue 2024
TTOO reported a revenue (TTM) of $7.19 million for the quarter ending December 31, 2023, a -67.75% decline year-over-year.
T2 Biosystems Inc (TTOO) Net Income 2024
TTOO net income (TTM) was -$50.08 million for the quarter ending December 31, 2023, a +19.23% increase year-over-year.
T2 Biosystems Inc (TTOO) Cash Flow 2024
TTOO recorded a free cash flow (TTM) of -$48.33 million for the quarter ending December 31, 2023, a +5.18% increase year-over-year.
T2 Biosystems Inc (TTOO) Earnings per Share 2024
TTOO earnings per share (TTM) was -$146.00 for the quarter ending December 31, 2023, a +89.80% growth year-over-year.
About T2 Biosystems Inc
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Cap:
|
Volume (24h):